Helen Ho, Ph.D.
Chief Business and Strategy Officer
Helen has two decades of experience in building fully integrated biopharmaceutical companies that have brought transformative medicines to patients with cancer and rare diseases. At Parabilis, she leads corporate growth strategy, business development and portfolio management, and oversees corporate communications, alliance management and new product planning. Helen most recently served as Chief Business Officer of Blueprint Medicines. She joined Blueprint Medicines in 2018 and, throughout her tenure, was responsible for driving the company’s corporate strategy and leading business development, alliance management, portfolio leadership and new product planning. She also served as Chair of the Portfolio Management Team, accountable for the company’s portfolio strategy.
Prior to joining Blueprint Medicines, Helen served as Vice President and Head of Corporate Development at TCR2 Therapeutics where she led portfolio strategy, business development and investor and public relations, culminating in the closing of a $125M Series B crossover financing. Prior to TCR2 Therapeutics, Helen was Director, Business Development and Operations at Agios Pharmaceuticals where she played a broad role in company building during her six-year tenure having led the business development licensing function, supported the company’s IPO and built its Rare Genetic Disorders and Immuno-Oncology franchises.
Previously, Helen was a management consultant at L.E.K. Consulting, leading engagements from both Boston and Shanghai offices. She holds a Ph.D. in Cell Biology from Yale University and a B.S. in Biochemistry from University of California, Los Angeles.
